FORUM INFORMATION

Date： May 26-27, 2025

Venue：The Chinese University of Hong Kong,

Cheng Yu Tung Building

Hong Kong Global Cancer IP Investors Forum aims to provide an effective platform for biomedical R&D entrepreneurs, investors, pharmaceutical multinationals, scholars, and professional service providers for intellectual property (IP) transactions, licensing, investment, and financing.

The forum is jointly organized by the Faculty of Medicine, The Chinese University of Hong Kong and the Chinese Manufacturers' Association of Hong Kong. With full support from multiple institutions including Invest Hong Kong, the Office for Attracting Strategic Enterprises, Hong Kong Productivity Council, Hong Kong General Chamber of Commerce, Federation of Hong Kong Industries, The Chinese General Chamber of Commerce, Tsinghua Science Park, as well as numerous sponsors, it establishes an international and professional exchange platform. This initiative brings together China and global-leading cancer technology developers, renowned scholars, industry leaders, and investment institutions (including family offices, venture capital firms, private equity funds, angel investors, banks, and multinational biopharmaceutical corporations) to jointly explore new investment and financing opportunities, facilitate overseas licensing collaborations, and collectively advance Hong Kong's position as a world-class healthcare hub and a global intellectual property (IP) trading center for cancer technologies.

● Day 1
Insights on Successful Commercialization of Scientific Research. Opportunities and Challenges in Biomedical Technology IP Investment and Financing

● Day 2
How Hong Kong Can Play the Role of a Biomedical Technology IP Center, providing a Superior Base for Biomedical Technology and Innovation Development, Supporting Enterprises to Develop the International Market, and Helping Overseas Enterprises Enter the Mainland Market, in Line with National and Regional Development

● One-on-One Meetings:
The conference provides opportunities for one-on-one meetings between pharmaceutical technology companies and investors (invited companies need to submit company profiles to all participating investors through the organizing agency one month before the meeting).

● Engage with Top Experts and Industry Investors
The forum has invited internationally renowned scholars and industry leaders, including Professor Dennis Lo, Professor Tony Mok and Professor Anthony Chan from The Chinese University of Hong Kong, as well as Sean Cao, Operating Partner of CBC Group, and Liu Da, Managing Director of CR-CP Life Science Fund. They will share the latest research findings and investment trends in biomdical technology, providing valuable industry investment insights to attendees.

● Expand Global Investment and Financing Networks
Hong Kong has a mature capital market, with the Stock Exchange of Hong Kong, family offices, venture capital firms, private equity funds, angel investors, banks, insurance companies and other financial institutions facilitating the efficient development of financial services. This forum will attract numerous industry representatives from China and overseas, including anti-cancer technology R&D enterprises and pharmaceutical multinationals, providing excellent opportunities for start-ups seeking financing and investors interested in cutting-edge technology to expand their global networks.

● Utilize IP Transactions and Investment for business development
With the increasing number and amount of licensing transactions by domestic pharmaceutical companies, the demand for anti-cancer drug IP transactions is growing. The forum will provide an efficient platform for IP transactions, licensing, investment, and financing, promoting business matching and driving the commercialization of biomedical technology.

● Gain Insight into Cancer Technology Commercialization
The forum will feature keynote speeches and panel discussions on the progress and major trends in cancer technology, covering topics such as new diagnostic techniques, new medical therapies, and medical AI, as well as related IP value enhancement. Attendees will have the opportunity to learn about the latest cancer treatment technologies and equipment and explore collaboration and investment opportunities.

● Bio Technology R&D Enterprises
Although the forum is focussed on cancer technology, we welcome other outstanding biomedical R&D companies to participate, showcasing the latest technological achievements, and seeking investment and collaboration opportunities.

● Investors
Including family offices, venture capital firms, private equity funds, angel investors, etc., seeking high-potential investment projects.

● Pharmaceutical Multinationals
To understand industry trends and expand the global market.

● Scholars and Researchers
To share research findings and engage with industry leaders.

● Professional Service Providers
Including legal, financial, and intellectual property fields, providing professional support services.

Disclaimer: The information published on the forum does not constitute investment advice. You must carefully evaluate and assess the merits and risks of any investments and, where in doubt, you should consult professional advisors accordingly. We do not accept responsibility for any loss which may arise from reliance on information or materials published on the forum. All information is for reference only and is subject to final confirmation from the Global Cancer IP Promotion Alliance Limited.

We shall under no circumstances be liable for any (i) loss of income; loss of profit; loss of opportunity or damage to the participant’s reputation; and/or (ii) indirect; special; incidental; or consequential loss or damage, whatsoever and howsoever such loss, damage or delay was caused, whether from contract, breach of statutory duty, by indemnity tort (including negligence) or otherwise.